fbpx
Connect with us

BUSINESS

Medmen Enterprises Inc (OTCMKTS:MMNFF) Positioning Itself For Better Times Ahead

Published

on

The expanding cannabis market is getting industry players excited as they take steps to position themselves to serve the clients. One such company is Medmen Enterprises Inc (OTCMKTS:MMNFF). The Canadian cannabis giant announced the acquisition of retail locations that will bolster its strategy. Per a press statement, it controls leases in “Ft. Lauderdale, Miami Beach, West Palm Beach, St. Petersburg and Key West.” These are important additions to the company’s list of prime retail locations in Florida.

Rising demand for medical cannabis

The news comes shortly after the company entered a deal in which Medmen offered shares to Eight Capital. In the offering, Eight Capital takes control of over 13 million units valued at CAD$75 million. According to a September 6, 2018, press release, each unit comprises “one Class B Subordinate Voting Share of the Company.” As much as the deal gives voting shares to Eight Capital, Medmen has more cash on its hands to use. The release reveals that the Medmen Enterprises Inc (OTCMKTS: MMNFF) will use the funds to facilitate an expansion drive.

Further, the foray into the Florida market is a testimony of a company that is looking for maximum returns. The market is quickly expanding and analysts put it at the second place after California in the United States. Market analysts attribute the rapid rising of medical cannabis demand as a result of tourists flooding the region. Importantly, the large Florida population is a prime market for the medical cannabis products.

Medmen Enterprises Inc (OTCMKTS:MMNFF) to use Florida for a national strategy

In fact, Medmen believes the foray into Florida will help propel the company to greater heights. In his words, Adam Bierman, MedMen CEO and co-founder says:

“Our entry into Florida through this acquisition demonstrates our growing national footprint as well as our ability to execute. Our real estate team is hard at work preparing to put MedMen branded stores in the most coveted locations in Florida – locations in highly desirable and defensible market areas with high foot traffic and proximity to popular brand retailers.”

Meanwhile, the cannabis giant is offering units of MM Enterprises USA, LLC, its subsidiary in the USA. The offering launches on the first day of January, 2019.

BUSINESS

Abattis Bioceuticals Corp (OTCMKTS:ATTBF) Unveils “Comfort” A New Product Line Targeting Chronic Pain & Inflammation

Published

on

The pharmaceutical industry is set to receive a new boost; thanks to Abattis Bioceuticals Corp (OTCMKTS:ATTBF). The cannabis company well – known for its diversification says it is on the verge of releasing a new chronic pain and inflammation product. The launch of the product known as “Comfort” is as a result of an extensive research by the Cannabis solution provider.

Abattis has been holding onto this vision of enlarging its product line in an effort to propel its vision. This is the more reason it has invested heavily in research, partnerships and comparison studies. It is already working on a phase 1 study, targeting the exploration and the development of nanoemulsified and liposomal platforms. The study is in partnership with the University of British Columbia and Mitacs.

Comfort will address the needs of the severe disabling condition

Chronic pain and inflammation is a growing problem. Reports from the Industry of Medicine indicate that close to 100 million people in North America are at the mercy of this condition. The condition affects the internal systems of a person, which in return fail to produce the required endogenous chemicals. What follows is severe pain known to last for too long.

The report further explains how millions of people are not able to access the necessary medical treatments. They are either too expensive or are not available. This not only brings along lost productivity but in the very severe cases have resulted in death.

However, Abattis President and CEO, Rob Abenante cited, “With Comfort, we hope to address a severely disabling condition that affects a large proportion of our population.”

Abattis is confident about its Research and Development strategy

Apart from partnering with a number of corporations, Abattis is also seeking to obtain a Health Canada dealer’s license. If approved, the company will be able to trade in Cannabis flower and oils. It will also integrate into its business key acquisitions. The company is seriously engaged in growing of its retail distribution. It will leave nothing to chance when it comes to research and development.

Clearly, Abattis is establishing a footprint in the cannabis industry from its research and development work.

Continue Reading

BUSINESS

Medical Marijuana Inc (OTCMKTS:MJNA) Announces The Launch Of Real Scientific Canada Across Canada

Published

on

Medical Marijuana Inc (OTCMKTS:MJNA) is quickly making a name for itself having introduced a new subsidiary, Real Scientific Canada. The company says the brand extend its operations into the Canadian market through the help of Salvation Botanicals, Ltd. This is a Canadian extraction and formulation company, which has signed a consulting agreement with Medical Marijuana

Through its Real Scientific Hemp Oil, Real Scientific Canada will help in growing and expanding the global cannabis market. The oil is within a product line, which comes with several different formulations the likes of RSHO Gold Label. Apparently, it was the first CBD product line in the U.S. to hit the state lines.

Medical Marijuana Inc. has rapid revenue growth and dedication to cannabis education

Medical Marijuana Inc. is on record as being the first-ever publicly traded cannabis company in the U.S. It is also at the forefront in its fight to give a new look to the ever-evolving cannabis market. This is the sole reason why it will continue to rededicate its energy towards cannabis education in the U.S.

According to Kenneth Smith, the Medical Marijuana, Inc. Director of Canadian Operations the cannabis industry is experiencing a very exciting moment. The company’s CEO Dr. Stuart Titus shared in the same sentiments quoting, “We recognize our customers’ ever-growing needs for cutting-edge products and we aim to meet them in this new legal recreational market in Canada.”

Real Scientific Canada is rich in history for its innovative lines of cannabis products

The company’s oil is has obtained import permit in Paraguay, Mexico, and Brazil. On the other hand, it has created an incredible rapport with various authorities as it continues to create awareness within the industry. Its goal, which is to help customers feel their best is in line with the mission for Medical Marijuana. The two are working hand in hand to premier cannabis and hemp industry innovators.

In other news Medical Marijuana has equally launched a CBD hemp oil product in Brazil through its subsidiary HempMeds Brasil. The approval of the new 5000 mg CBD hemp oil liquid came after a series of consultations with the Brazilian Health Regulatory Agency ANVISA. This is another great milestone for the company.

Continue Reading

BUSINESS

VIVO Cannabis Inc (OTCMKTS:VVCIF) Enters Into A $5 Million Strategic Agreement With Westleaf Cannabis Inc

Published

on

VIVO Cannabis Inc (OTCMKTS:VVCIF) has made such a great milestone in advancing its operations. The company based in Napanee, Ontario has entered into an agreement with a Westleaf Cannabis Inc. worth $5 million. The duo’s strategic arrangement will give VIVO an upper hand as it strives to roll out its cannabis retail operations in Canada. It is worth noting that the Cannabis market is becoming appealing to customers thus the rapid expansion.

Several medical cannabis formulations are on record for being beneficial to patients suffering from particular conditions. Hence, any move to improve their quality standards will create more desire for use from health care professionals and patients.

The partnership reflects VIVO’s commitment to research and innovation

VIVO has developed such a strong focus on quality and innovation as it continues to push the growth of its business. The primary goal is in creating novel products and particularly for the international markets, which seems to be very stable. Some of these markets include Germany and Australia. The company has established a tight network of specialty medical cannabis clinics through its Harvest Medicine.

Nonetheless, according to the company’s CEO, Barry Fishman, their commitment is in pursuing opportunities across the full value chain. Fishman says, “VIVO is committed to providing high-quality products for the Canadian recreational cannabis market. We continue to build our presence in the adult-use market with this strategic investment in Westleaf.”

What will the integrated strategy offer the cannabis industry?

Westleaf’s goal is to offer innovative retail experiences to the Cannabis industry through premium cannabis production. Besides, the company is expanding its wings to Alberta and Saskatchewan with the construction of state-of-the-art cannabis production facilities. On the other hand, VIVO is anticipating to develop new formulations, which will benefit current and future medical patients.

All these efforts put together will give a strong endorsement to the expansion of the cannabis industry. What seems like a well-integrated strategy will place the industry at a high caliber level according to President and CEO of Westleaf, Scott Hurd.

Through the investment, VIVO will get 5,882,353 units of Westleaf whereby each of the units is equivalent to one Westleaf common share.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories